.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Scientists at the National Institute of Nutrition (NIN) recently developed a poly-herbal blend for diabetes and obesity management. This innovative formulation combines five common kitchen ingredients: ginger, cinnamon, black pepper, amla, and turmeric. Beyond simple glucose control, the extract targets inflammation and oxidative stress. Consequently, it addresses the root causes of long-term diabetic complications that affect the heart and kidneys.
Researchers selected these five herbs after screening nearly 200 functional foods. They specifically focused on inhibiting advanced glycation end products (AGEs). These compounds contribute significantly to chronic damage in patients with diabetes. The team tested each ingredient individually before establishing a precise, scientifically backed composition. Furthermore, preclinical studies showed promising results in reducing both blood glucose and body weight. Because it is not a random mixture, the formulation ensures consistent potency.
The National Institute of Nutrition clarifies that this extract serves as an add-on therapy. It is not a replacement for standard medical treatments like metformin or insulin. Instead, it offers a protective effect for the eyes, nerves, and vascular system. Currently, the formulation is standardized at the laboratory level. Human clinical trials are scheduled to begin shortly and will likely last up to a year. This development highlights a significant move toward integrative health solutions in India. Doctors may soon have a scientifically validated herbal tool to complement existing diabetic care plans.
Q1: What specific ingredients comprise this new formulation?
The extract consists of a precise, evidence-based blend of ginger, cinnamon, black pepper, amla, and turmeric.
Q2: Can this herbal blend replace existing diabetes medication?
No, researchers emphasize that the blend is intended as an add-on therapy to existing clinical treatments, not a substitute.
Q3: How long will the clinical trials for this extract take?
The clinical trials are expected to run for 9 to 12 months, with a full evaluation completed within 18 months.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
NIN scientists develop a poly-herbal extract using five common herbs to manage diabetes, obesity, and long-term complications through scientific integration...
6 months ago
Explore vital recurrent stroke predictors in lacunar stroke patients managed with intensive blood pressure lowering. This analysis examines trial findings from SPS3 to uncover residual vascular risks, metabolic factors, and targeted secondary prevention strategies for high-risk neurological patients.
Today
A comprehensive scoping review synthesises evidence linking prenatal maternal mental health to long-term offspring neurodevelopment, evaluating neuroendocrine, inflammatory, and epigenetic pathways while highlighting clinical screening and future research priorities.
Today
The Directorate General of Health Services directs Indian states to halt the hazardous reuse and reprocessing of single-use medical devices. Discover regulatory implications under the Drugs and Cosmetics Act, critical infection risks, legal liabilities, and operational changes required across clinical specialties.
Today
Mitochondria-targeted nanoparticles self-assembled from EGCG and L-glutamic acid effectively restore mitochondrial homeostasis, suppress synovial inflammation, and attenuate chondrocyte senescence in osteoarthritis, offering a promising disease-modifying nanotherapy.
Today
India is advancing preventive healthcare by integrating genomics, artificial intelligence, and quantum technologies. With the SANGAM programme sequencing one million Indian genomes, clinicians can unlock personalized therapies, detect cardiometabolic risks early, and curb the burden of diabetes and heart disease.
Today
